The firm is a multinational biopharmaceutical corporation. The firm develops and produces medicines, vaccines and consumer health care products. The firm looks to invest in/partner with academic research and start-up companies for developing innovative therapies and delivering value to the company. The firm has established a number of partnering models including Academic & Start-Up Company Partnerships, Alternative Development / Funding Models, Centers for Therapeutic Innovation, Global Scouting, Open Innovation Portal and a Corporate Venture Fund. The firm also takes part in equity rounds, usually with rights attached. The company is open to make co-development deals to help early-stage biotech companies, and is currently looking for new investment opportunities across the globe with a focus in North America, Europe, and Asia.c
The firm is currently looking for innovative therapeutics and medical technologies targeting the following areas: Cardiovascular & Metabolic Diseases, Immunology & Inflammation, Neuroscience, Oncology (including Immuno-Oncology), Rare Diseases (Gene Therapy as a platform), and Vaccines. In neuroscience, the firm is focused on neurodegenerative diseases, particularly technology in Alzheimer’s and Parkinson’s disease, and is open to preclinical (conception) to Ph III technology in this strategy. Neuroscience companies in neuroinflammation (i.e. microglia) and other emerging CNS areas, including CNS rare diseases and symptom-treating technology, require robust Ph II (or beyond) data. For rare indications, the firm requires a therapeutic approach that directly addresses the genetic cause of the disease. The firm is also open to other life science technologies that may speed up the development process, including lab technology and drug development enabling technologies. The firm also seeks in-licensing products for development. Overall, the firm is open to all stages of development, as the firm has separate teams to encompass all phases of development from preclinical to commercial stages.
The firm collaborates – in multiple formats – with both privately held and public life science companies with experienced management teams, innovative technologies, and an established scientific unit.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply